ALLR on Nasdaq
Allarity Therapeutics, Inc.
$0.84 down 0.03 (3.79%)Price as of Oct 15, 2026 at 17:33 UTC
Last updated Oct 16, 2026.
Overview
Compare with Vyome Holdings, Inc, Immuneering Corp or Edesa Biotech, Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development100¢$6.6M
Out of $320.0K in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | $320.0K | $0 |
| Research and development | $6.6M | $6.1M |
| Impairment of intangible assets | $0 | $9.7M |
| General and administrative | $6.3M | $11.4M |
| Total operating expenses | $12.9M | $27.2M |
| Loss from operations | -$12.6M | -$27.2M |
| Interest income | $801.0K | $533.0K |
| Interest expenses | -$185.0K | -$653.0K |
| Foreign exchange gains (losses) | $757.0K | -$212.0K |
| Change in fair value adjustment of warrant derivative liabilities | $1.0K | $2.7M |
| Total other income | $1.4M | $2.3M |
| Loss before income tax expense (benefit) | -$11.2M | -$24.9M |
| Income tax expense (benefit) | $0 | -$381.0K |
| Net loss | -$11.2M | -$24.5M |
| Net loss attributable to common stockholders | -$11.2M | -$25.2M |
| Net loss per common share, basic and diluted (in dollars per share) | -$0.78 | -$15.65 |
| Weighted average common shares outstanding, basic and diluted (in shares) | 14.4M shares | 1.6M shares |
| Change in cumulative translation adjustment | -$667.0K | $57.0K |
| Total comprehensive loss | -$11.9M | -$24.5M |
Every line of the balance sheet in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash | $14.7M | $19.5M | |
| Receivables from ATM sales | $0 | $1.4M | |
| Other current assets | $265.0K | $115.0K | |
| Prepaid expenses | $2.1M | $507.0K | |
| Tax credit receivable | $866.0K | $770.0K | |
| Total current assets | $17.9M | $22.3M | |
| Property, plant and equipment, net | $330.0K | $309.0K | |
| Total assets | $18.3M | $22.6M | |
| Accounts payable | $4.3M | $4.2M | |
| Accrued expenses and other current liabilities | $2.7M | $5.2M | |
| Warrant derivative liability | $0 | $1.0K | |
| Income taxes payable | $81.0K | $74.0K | |
| Convertible promissory note and accrued interest | $1.4M | $1.4M | |
| Total current liabilities | $8.4M | $10.8M | |
| Total liabilities | $8.4M | $10.8M | |
| Common stock, $0.0001 par value (250,000,000 shares authorized); 19,030,619 and 7,302,797 shares issued and 16,080,980 and 7,302,797 outstanding at December 31, 2025, and December 31, 2024, respectively | $3.0K | $1.0K | |
| Additional paid-in capital | $144.2M | $131.1M | |
| Accumulated other comprehensive loss | -$1.0M | -$354.0K | |
| Accumulated deficit | -$130.2M | -$119.0M | |
| Treasury stock, at cost; 2,949,639 shares | -$3.2M | $0 | |
| Total stockholders equity | $9.8M | $11.8M | -$2.8M |
| Total liabilities and stockholders equity | $18.3M | $22.6M | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 250.0M shares | 250.0M shares | |
| Common stock, issued (in shares) | 19.0M shares | 7.3M shares | |
| Common stock, outstanding (in shares) | 16.1M shares | 7.3M shares | |
| Treasury, shares (in shares) | 2.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$11.2M | -$24.5M |
| Depreciation and amortization | -$13.0K | $9.0K |
| Intangible asset impairment | $0 | $9.7M |
| Common stock issued for services | -$200.0K | -$336.0K |
| Stock-based compensation expense | $482.0K | $71.0K |
| Unrealized foreign exchange gain | $1.2M | -$126.0K |
| Non-cash interest expense | $185.0K | $230.0K |
| Change in fair value of warrant derivative liabilities | -$1.0K | -$2.7M |
| Deferred income taxes | $0 | -$446.0K |
| Other current assets | -$150.0K | $94.0K |
| Unearned revenue | $0 | $207.0K |
| Tax credit receivable | -$96.0K | $45.0K |
| Prepaid expenses | -$1.6M | $274.0K |
| Accounts payable | -$1.1M | -$4.1M |
| Accrued liabilities | -$2.7M | $3.5M |
| Income taxes payable | $7.0K | $15.0K |
| Net cash used in operating activities | -$14.8M | -$17.4M |
| Purchase of property and equipment | -$8.0K | -$298.0K |
| Net cash used in investing activities | -$8.0K | -$298.0K |
| Proceeds from 3i promissory notes | $0 | $1.3M |
| Repayment of 3i debt | $0 | -$1.3M |
| Proceeds from ATM sales of common stock, net of issuance costs | $11.1M | $37.4M |
| Net proceeds from common stock and pre-funded warrant issuance | $2.7M | $0 |
| Proceeds from issuance of Convertible Redeemable Series A Preferred Stock | $0 | $2.9M |
| Redemption of Convertible Redeemable Series A Preferred Stock | $0 | -$3.5M |
| Common stock repurchase | -$3.2M | $0 |
| Net cash provided by financing activities | $10.6M | $36.8M |
| Net increase (decrease) in cash | -$4.2M | $19.1M |
| Effect of exchange rate changes on cash | -$667.0K | $225.0K |
| Cash paid for interest | $0 | $423.0K |
| Cash received for interest | $801.0K | $503.0K |
| Stock issued in conjunction with consulting agreement | $200.0K | $90.0K |
| Conversion of Series A Redeemable Preferred Stock to common stock | $0 | $1.8M |
Recent filings
- Oct 9, 20264
- Oct 1, 20268-K CURRENT REPORT
- Sep 29, 20268-K CURRENT REPORT
- Sep 16, 20268-K CURRENT REPORT
- Sep 14, 20268-K CURRENT REPORT
- Aug 14, 202610-Q
- Aug 14, 20268-K CURRENT REPORT
- Jul 1, 20268-K CURRENT REPORT
- Jun 22, 20268-K CURRENT REPORT
- Jun 2, 20268-K CURRENT REPORT
- May 15, 202610-Q
- May 14, 20264 OWNERSHIP DOCUMENT
- May 11, 20263
- May 11, 20264 OWNERSHIP DOCUMENT
- May 8, 20268-K CURRENT REPORT
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2Yahoo FinanceALLR quote
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10